Open AccessS0861 Comparative Risk of Serious Infections With Tumor Necrosis Factor-α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases
Author(s) -
Siddharth Singh,
Herbert C. Heien,
Jeph Herrin,
Parambir S. Dulai,
Lindsey R. Sangaralingham,
Nilay D. Shah,
William J. Sandborn
Publication year - 2020
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.907
H-Index - 252
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/01.ajg.0000705492.87799.ce
Subject(s) - vedolizumab , medicine , inflammatory bowel disease , ulcerative colitis , hazard ratio , proportional hazards model , cohort , retrospective cohort study , crohn's disease , gastroenterology , disease , confidence interval